Cardiology

Having a healthy heart is an important part of disease management for people with narcolepsy who face an increased risk of cardiovascular and metabolic comorbidities.

An analysis of data from the National Inpatient Sample suggests pregnancies conceived by assisted reproductive technology carried a 1.7- and 2.5-fold increase in risk for arrhythmia and acute kidney injury compared to those conceived without ART.

The expanded indication for the CardioMEMS HF System includes patients with NYHA Class II heart failure and elevated levels of natriuretic peptides.

With the field already booming with capability, a Penn Medicine expert discusses her team's research into finding the right tools for the right patients and clinicians.

Severe financial strain was associated with a 61% increase in 180-day mortality risk, compared to patients with no strain.

A pilot trial from Perelman showed patients were far more likely to provide blood pressure levels via text than a standard online patient portal.

More than 1-in-3 patients with T2D and ASCVD in a large cohort were receiving none of the 3 evidence-based therapies associated with significant cardiovascular benefit, including lipid-, blood pressure-, and glucose-lowering pharmacotherapy.

Higher variability of adiposity indices was associated with significantly increased risk of CVD outcomes in standard of care, but not in the intensive lifestyle intervention group.

Merle Myerson, MD, EdD, discusses her perspective on the themes of cardiology in 2021 and offers a prediction of what she believes could end up being the theme of 2022.

A retrospective cohort study suggests users of DOACs were at a 16% lower risk of developing macrovascular complications, a 21% lower risk of microvascular complications, and a 22% lower risk of mortality compared with warfarin users among a population of patients with diabetes and atrial fibrillation.

Data show fewer than 1 in 20 patients with diabetes and ASCVD were prescribed a high-intensity statin, either an ACEI or ARB, and either an SGLT2I and/or a GLP-1RA.

Findings from REDUCE-IT show icosapent ethyl was projected to be cost-effective compared with standard care in patients with high CV risk despite statin therapy.

Takeaways of the REDUCE-IT trial of icosapent ethyl as treatment for dyslipidemia and hypertriglyceridemia.

An overview of the REDUCE-IT trial of icosapent ethyl for the management of triglycerides and prevention of cardiovascular events.

A new study in JAMA Network Open provides an overview of the cost-effectiveness of icosapent ethyl at multiple prices in high-risk patients with hypertriglyceridemia despite statin therapy.

A pilot trial suggests telemedicine methods need to be tailored to reach adversely affected populations including Black patients on Medicare or Medicaid.

New data provides insight into risk factors that could improve risk stratification of prediction models for cardiovascular disease among patients with chronic kidney disease.

Data show atherosclerotic burden was heterogeneous across LDL-C levels and risk is shown to be consistently associated with plaque burden.

Data from Medicare beneficiaries provide insight into the risk of stroke associated with a diagnosis of COVID-19 among older adults, which results suggest peaks within the first 3 days of diagnosis.

AN analysis of the UK Biobank cohort provides insight into the increased risk of cardiovascular disease associated with gestational diabetes, including a 69% increase in risk of stroke and 42% increase in risk of heart failure later in life.

Patients with a positive genetic test showed higher mortality rates compared to genotype-negative patients.

A meta-analysis presented at ISC 2022 suggests the risk of in-hospital mortality for stroke-related admissions was 42% greater among patients hospitalized during the pandemic compared to prepandemic.

Using a pair of composite scores for measuring sleep health, new research from USF demonstrates the impact poor sleep health can have on risk of cardiovascular disease among adults in midlife.

A higher percentages of patients treated with tirzepatide had HbA1c less than 7% versus those treated with placebo (85%-90% versus 34%).

Data from the PATH-BP study suggests patients receiving daily acetaminophen experienced significant increases in systolic and diastolic blood pressure after just 2 weeks of receiving the medication.

The NDA has been assigned standard review with a PDUFA target action date in late November 2022.

A recent analysis of data is providing insight into the use of aspirin for preeclampsia prevention among women with prepregnancy obesity, hypertension, or diabetes.

No difference was observed between atrial shunt placement and sham in the endpoint of CVD death, non-fatal ischemic stroke at 12 months, and rate of total heart failure events at 24 months.

In commemoration of Wear Red Day, here's a breakdown of how US regions differ in cardiovascular disease burden among women.